Venture Funding Deals: Locana Gets Ready To Take On ALS, Huntington's With Gene Editing
The series A fundraising will help Locana bring CRISPR gene editing to diseases with dysfunctional RNA. Artizan and OncoMyx are among the other firms with recent series A rounds.
You may also be interested in...
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Eight $1bn+ alliances were penned in July. Topping the list was a potential $2.8bn deal under which Alnylam granted Roche exclusive global rights outside the US to develop and commercialize its Phase II hypertension candidate zilebesiran. The companies will co-develop zilebesiran in the US.
During Q2, biopharma merger and acquisition deal value reached $29bn and drew in $36.8bn in potential deal value from alliances. Device company M&A values reached $988m, while in vitro diagnostics and research tools players’ M&A activity totaled $450m.